Comment on “Randomised Comparison of a Bioresorbable Everolimus‐Eluting Scaffold with a Metallic Everolimus‐Eluting Stent for Ischaemic Heart Disease Caused by de Novo Native Coronary Artery Lesions: the 2‐Year Clinical Outcomes of the Absorb Ii Trial”